A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Treating to goal: challenges of current management
2004
European Journal of Endocrinology
Extensive evidence supports the benefits of treating to glycated haemoglobin (HbA 1c ) goal, both in terms of health and economic outcomes. As shown by the UK Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications Trial (DCCT), the risk of patients with type 2 diabetes developing vascular complications is strongly correlated with HbA 1c levels and the duration of poor glycaemic control. Moreover, good glycaemic control significantly reduces the risk of complications. In
doi:10.1530/eje.0.151t003
pmid:15487977
fatcat:hs5yihmoc5baxagg2g2b4fbrke